Is Bristol-Myers Squibb Stock (BMY) Halal? A Complete Analysis

The Short Answer

Bristol-Myers Squibb stock (BMY) is generally considered halal by most Islamic scholars and Sharia screening criteria, subject to verifying the current debt-to-market-cap ratio. BMY is a US-headquartered global biopharmaceutical company focused on prescription specialty medicines across oncology, hematology, immunology, cardiovascular, and neuroscience.

Pharmaceutical development, manufacture, and distribution is unambiguously permissible at the activity level under standard Sharia methodology. The financial-screen consideration is leverage — BMY took on significant debt to fund the 2019 Celgene acquisition and the 2023 Mirati Therapeutics acquisition. Verify the consolidated debt-to-market-cap ratio against the 33% Sharia threshold at the time of investment.

Sharia Screening Methodology

Islamic scholars use several criteria to screen stocks:

• Business activity screen: Is the company's primary business halal?
• Debt ratio: Total debt / market cap must be under 33%
• Interest income: Interest income / total revenue must be under 5%
• Haram revenue: Revenue from haram sources must be under 5%
• Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)

Bristol-Myers Squibb's Business Activity

BMY operates as a global biopharmaceutical company focused on prescription specialty medicines across major therapeutic categories:

• Oncology: Opdivo (nivolumab), an anti-PD-1 immune checkpoint inhibitor with broad oncology indications; Yervoy (ipilimumab), an anti-CTLA-4 checkpoint inhibitor often used in combination with Opdivo; Revlimid (lenalidomide) for multiple myeloma; Pomalyst, Sprycel, and the broader oncology portfolio
• Hematology: Reblozyl for anemia in beta-thalassemia and myelodysplastic syndromes; Breyanzi, an autologous CD19-directed CAR-T therapy for relapsed/refractory lymphoma
• Immunology: Eliquis (apixaban), a direct oral anticoagulant co-marketed with Pfizer that is the largest-selling drug in the cardiovascular category globally; Orencia, Zeposia, Sotyktu for psoriasis, and other immunology medicines
• Cardiovascular medicines: The broader cardiovascular franchise
• Neuroscience: Camzyos for obstructive hypertrophic cardiomyopathy

The pipeline includes additional programs in oncology, hematology, immunology, and neuroscience. Pharmaceutical development is unambiguously permissible at the activity level under standard Sharia methodology — BMY's medicines serve to preserve life and treat serious disease.

Concerns to Be Aware Of

1. Debt-to-Market-Cap Ratio Elevated by Acquisitions

BMY took on significant debt to fund the 2019 Celgene acquisition (approximately $74 billion) and the 2023 Mirati Therapeutics acquisition. The consolidated debt-to-market-cap ratio sits in a range that should be verified against the 33% Sharia threshold at the time of investment depending on the share price. BMY has been deleveraging through free cash flow generation.

2. Porcine-Derived Materials in Some Formulations

Some pharmaceutical products may contain trace porcine-derived or other animal-derived materials in manufacturing or formulation. Scholars generally classify medicines as permissible under necessity (darura) even where alternative formulations are unavailable.

3. Patent-Cliff Exposure

BMY faces meaningful patent-cliff exposure on Revlimid (already underway with generic competition that ramps through 2026), Opdivo (loss of exclusivity beginning around 2028), and Eliquis (loss of exclusivity beginning in 2026-2028). This is a business-quality and revenue-concentration consideration rather than a Sharia screen concern.

4. Minor Interest Income

BMY holds cash and short-term investment balances that generate small interest income. This is well below the 5% Sharia threshold but warrants purification of a small portion of dividends.

Financial Ratios (2025)

Based on BMY's most recent financial statements:

• Total Debt / Market Cap: Elevated by Celgene and Mirati acquisitions — verify against 33% threshold ⚠️
• Interest Income / Revenue: Well under 5% ✅
• Haram Revenue: Negligible ✅
• Business Activity: Permissible pharmaceutical ✅

Verdict from Major Screening Agencies

Bristol-Myers Squibb stock is generally screened as compliant (halal) with purification by:

• Zoya App — Compliant with purification, subject to leverage verification ⚠️
• MSCI Islamic criteria — Verify current inclusion based on debt screening methodology ⚠️
• Most major Sharia advisory boards — Compliant with purification, subject to leverage verification ✅

Bottom Line

Bristol-Myers Squibb (BMY) is generally halal with purification for Muslim investors, subject to verifying the current debt-to-market-cap ratio against the 33% Sharia threshold. The core business — biopharmaceutical development, manufacture, and distribution of prescription specialty medicines — is unambiguously permissible at the activity level. Apply purification of any small interest-income component in the income statement.

For Muslim investors seeking US large-cap pharmaceutical exposure, BMY offers concentrated oncology exposure through Opdivo and the Celgene-acquired franchise (Revlimid, Pomalyst), plus the Eliquis cardiovascular blockbuster, comparable in profile to other halal-screened pharma names like Merck (MRK), AbbVie (ABBV), and Pfizer (PFE).